A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
Author
Summary, in English
Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).
Department/s
Publishing year
2016
Language
English
Pages
000133-000133
Publication/Series
RMD Open
Volume
2
Issue
1
Links
Document type
Journal article
Publisher
BMJ Publishing Group
Topic
- Rheumatology and Autoimmunity
Status
Published
Research group
- Internal Medicine - Epidemiology
ISBN/ISSN/Other
- ISSN: 2056-5933